The Utility of the WMS‐IV LM Subtest as an Inclusionary Measure in Early AD Trials

The present study found that less than half of participants did not screen fail due to MMSE or WMS-IV LM II inclusionary criteria. About 30% of participants did not screen fail on the MMSE but proceeded to screen fail on the WMS-IV LM II. This indicates that the WMS-IV LM II, which is being used as an indicator of episodic memory impairment, provided utility above and beyond a more general and brief screening tool such as the MMSE in these AD trials. Although the WMS-IV LM II may be cumbersome and lengthy to administer, it appears useful in improving classification of early AD participants.